⌕
Scribe Therapeutics · SCTX · Nasdaq
Tenet — · insufficient data
Compare
$15.37−6.05%At close
$15.37−0.99 (−6.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Scribe Therapeutics (SCTX) Earnings Forecast

Analysts expect Scribe Therapeutics (SCTX) to lose $3.68 a share in FY26, the average of 2 estimates as of Nov 17, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY26 consensus EPS
$−3.68
2 analysts
FY27 consensus EPS
$−2.52
2 analysts · low $−3.81, high $−1.72
Disagreement, FY26
$3.05
wide, $−5.56 to $−2.52

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 17, 2026 · we check it nightly

Analysts expect Scribe Therapeutics to lose $4.65 a share in FY28; 2 analysts publish an estimate for FY28.

Forward P/E · FY26E
n/m
a multiple of a loss is not meaningful
Revisions
Starts tonight
a revision needs two nights of one fiscal period to compare
Coverage · FY26
2 · 3
EPS estimates · revenue estimates

Are estimates going up or down lately?

Our record of this company's consensus starts with tonight's snapshot. A revision needs two of our own nightly snapshots of one fiscal period to compare, and nothing before the first is reconstructed, because a backfilled revision is a number we never observed.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 17, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from the first positive year on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY26
$−0.1B
2 analysts · low $−0.1B, high $−0.0B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · SCTX · FY26Nov 17, 2026
Implied, a share
Waiting

The arithmetic will run: EBITDA times your multiple is an enterprise value, plus $0.2B net cash and divided by 0.01B diluted shares, which is a price a share. Net cash from the Sep 30, 2026 balance sheet, diluted shares from the Sep 30, 2026 filing.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY28, estimates run from $−6.27 to $−3.02 around an average of $−4.65, drawn by 2 analysts.

FY26E2 analysts
$−5.56 to $−2.52 · $3.05 wide
FY27E2 analysts
$−3.81 to $−1.72 · $2.09 wide
FY28E2 analysts
$−6.27 to $−3.02 · $3.25 wide

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Scribe Therapeutics to lose $0.65 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$5.2M
2 analysts, 3.2 to 10.7 in $M

For the March quarter, analysts expect a loss of $0.63 a share.

Does Scribe Therapeutics usually beat or miss?

We have not been able to check a quarter yet. We hold no estimate for Scribe Therapeutics yet, so this record starts on the night we first do.

Before our record
Jun '25
Jun '26
Sep '26
Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. A quarter we did not hold an estimate for is never filled in after the fact.

The Street expects sales to grow −35.3% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

2 analysts publish an EPS estimate for FY26 and 3 publish revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by yearHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
32
FY26E
32
FY27E
32
FY28E

The full consensus, year by year

Consensus as of Nov 17, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
Not enough estimate history to chart yet.

Coverage thins with distance: 3 revenue estimates for FY26, 3 for FY28.

Diluted EPS · $filed · consensus average · band = low to high
Not enough estimate history to chart yet.

Out-year bands widen as fewer analysts publish: 2 EPS estimates for FY26, 2 for FY28.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY26E0.00.0 to 0.0n/ca−3.68−5.56 to −2.52n/ca−0.1−0.10.023 · 2n/m
FY27E0.00.0 to 0.0▼35.3%−2.52−3.81 to −1.72—−0.0−0.00.023 · 2n/m
FY28E0.00.0 to 0.0▲4.4%−4.65−6.27 to −3.02—−0.1−0.10.023 · 2n/m

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 2 EPS estimates for FY26, 3 for revenue. Not investment advice.

What do analysts expect Scribe Therapeutics to earn in FY26?

Analysts expect Scribe Therapeutics to lose $3.68 a share in FY26, the average of 2 estimates as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.